ArticleAMB Express2025
Antimicrobial and molluscicidal activities of Egyptian soil-derived Streptomyces rochei.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Actinomycetes, are abundant sources of bioactive secondary metabolites with potential antibacterial and molluscicidal effects. This work aims to isolate and characterize actinomycetes strains from Egyptian soil, emphasizing the evaluating their antibacterial efficiency, optimizating their metabolite production, and assessing molluscicidal activities against Biomphalaria alexandrina (B. alexandrina), an intermediate host of Schistosoma mansoni (S. mansoni). Nineteen actinomycetes isolates were screened for antimicrobial activity against Escherichia coli (E. coli), Salmonella typhi (S. typhi), Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus (S. aureus), Candida albicans (C. albicans), and Penicillium marneffei (P. marneffei). Isolate No. 10, later identified as Streptomyces rochei ASN (S. rochei ) via 16 S rDNA sequencing and phylogenetic analysis, exhibited broad-spectrum antimicrobial activity and was selected for further study. Production media optimization revealed that modified nutritional agar, starch as a carbon source, sodium nitrate as a nitrogen source, and 25 °C incubation maximized antimicrobial metabolite production. Antibacterial activity increased with extended incubation time, peaking at 8 days. Dose-dependent inhibition was observed when different concentrations (20-80%) of cell-free supernatant (CFS) from S. rochei ASN were applied to test pathogens, with S. aureus, C. albicans, and P. marneffei being most susceptible. Scanning electron microscopy revealed severe cellular and structural damage in treated microbes. The CFS also demonstrated significant molluscicidal activity, with LC₅₀ and LC₉₀ values of 26.85 ppm and 40.95 ppm, respectively. It inhibited the hatchability of B. alexandrina eggs in a concentration- and age-dependent manner, and exerted rapid, dose-dependent mortality against S. mansoni miracidia and cercariae. Histological examinations of exposed snails showed degeneration in both hermaphrodite and digestive glands, including disrupted acinar structures, damaged oocytes and spermatocytes, vacuolated digestive cells, and degenerated secretory cells. S. rochei ASN, isolated from Egyptian soil, exhibits potent antimicrobial and molluscicidal activities. Its bioactivity is significantly influenced by growth conditions and medium composition. The strain holds promise as a natural biocontrol agent against pathogenic microbes and snail vectors involved in schistosomiasis transmission, warranting further pharmacological and ecological investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.